Skip to Main Content

Paper Details

Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Nat Med
4
2018
KRAS, MEK, SHP2, actin, gastroesophageal cancer, wild
Author NameAffiliation
Steven E SchumacherThe Broad Institute of MIT and Harvard
Austin DulakDana-Farber Cancer Institute
Austin Dulak
Christopher Szeto
John Alan DiehlMedical University of South Carolina
Philipp MertinsThe Broad Institute of MIT and Harvard
Philipp MertinsMax Delbruck Center for Molecular Medicine
Steven A CarrThe Broad Institute of MIT and Harvard
Steven A CarrThe Broad Institute of MIT and Harvard
Rameen BeroukhimDana-Farber Cancer Institute
Rameen BeroukhimDana-Farber Cancer Institute
Rameen BeroukhimBrigham and Women's Hospital
Rameen BeroukhimHarvard Medical School
Rameen BeroukhimThe Broad Institute of MIT and Harvard
Adam J BassHarvard Medical School
Adam J BassBrigham and Women's Hospital
Adam J BassDana-Farber Cancer Institute
Adam J BassThe Broad Institute of MIT and Harvard
  • 1 - 18

Datasets